New combo therapy aims to extend life in aggressive lung cancer
NCT ID NCT03923270
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 28 times
Summary
This early-phase trial studies whether adding radiation to the chest followed by immunotherapy drugs (durvalumab alone or with tremelimumab or olaparib) can safely control extensive-stage small cell lung cancer after initial chemotherapy. About 25 adults whose cancer did not worsen after first-line chemo will receive these treatments. The goal is to find tolerable doses and check if the combination delays cancer progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.